Sanofi

News

x-ray image of human head with brain and electric pulses

Sanofi pauses enrolment in ex-US tolebrutinib trials

Sanofi has paused recruitment in its international phase 3 trials of BTK inhibitor tolebrutinib for multiple sclerosis, although it says studies aimed at getting US approval are on track to

Digital

AI tissue analysis enables rapid discovery of drug candidate...

AI could address the most significant issue in drug discovery, finds Ben Hargreaves, and also offers the potential to use tissue samples to create precision medicine for specific patient gr

News

Sanofi looks east with €300m Innovent cancer alliance

Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring two new cancer therapies as quickly as possible to patients in the world's second-

News

Bayer tops pharma rankings for diversity, inclusivity

The largest pharma companies have all set themselves ambitious targets in recent years to improve representation for women and minority communities in their businesses, but are they meeting

News

Chinese biotech Sironax raises $200m for RIPK1 pipeline

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for

News

Dupixent drives Sanofi to hike its full-year profit forecast...

Dupixent's march towards becoming one of the world's top-selling medicines continued at a healthy lick in the second quarter, allowing Sanofi to raise its full-year earnings forecasts.

Sanofi pauses enrolment in ex-US tolebrutinib trials

AI tissue analysis enables rapid discovery of drug candidate...

Sanofi looks east with €300m Innovent cancer alliance

Bayer tops pharma rankings for diversity, inclusivity

Chinese biotech Sironax raises $200m for RIPK1 pipeline

Dupixent drives Sanofi to hike its full-year profit forecast...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Sanofi

Editor's Picks